Liz Barrett, UroGen Pharma CEO (Photo by Steven Ferdman/Getty Images)
UroGen touts long duration of response for its bladder cancer chemotherapy gel
In a Phase 3 study, patients who saw a complete response at three months after receiving UroGen Pharma’s therapy had an 82% chance of having …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
